Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab.
View/
Volume
30
Pagination
1763 - 1766
Publisher
DOI
10.1038/leu.2016.41
Journal
Leukemia
Issue
Metadata
Show full item recordAuthors
Freeman, CL; Dixon, M; Houghton, R; Kreuzer, K-A; Fingerle-Rowson, G; Herling, M; Humphrey, K; Böttcher, S; de Costa, CS; Iglesias, V; Stilgenbauer, S; Gribben, J; Hallek, M; Goede, VCollections
- College Publications [5188]
Language
Licence information
Copyright statements
